Immunex/Roche
Executive Summary
Immunex will receive $5.5 mil. and royalties on worldwide sales of IL-2 and PEG IL-2, the latter from Roche licensee Cetus. In addition, the settlement of a longstanding royalty dispute includes the repurchase by Roche of an Immunex option to manufacture IL-2 for sale by Roche in the U.S.